Literature DB >> 2015955

Interaction of cremophor EL with human plasma.

M Kongshaug1, L S Cheng, J Moan, C Rimington.   

Abstract

1. Interaction of cremophor EL (CRM) with human plasma lipoproteins and nonlipoproteins has been investigated by ultracentrifugation. 2. VLDL has only a low or negligible capacity to bind CRM, i.e. there is little or no change in the optical absorption at 280 nm of VLDL when CRM is added. 3. A low density subfraction of low density lipoproteins seems to associate substantially with CRM at relatively low CRM concentrations (1-3 mg/ml), but such association is not evident for CRM concentrations in the region 12-116 mg/ml. 4. Low density lipoproteins (LDL) may act as a carrier for CRM-emulsions, yet there seems to be no concomitant change in the 280 nm optical absorption of the proteins of LDL. 5. The position in the gradient (i.e. in the centrifugation tube after centrifugation) of high density lipoproteins (HDL) is shifted towards lower density in the presence of 1-4 mg CRM/ml. For higher concentrations of CRM, a destruction of HDL can be observed: the HDL distribution is converted into a bimodal distribution of respectively lighter and heavier "HDL"-particles than the normal ones; the densities at the peaks of these distributions are approximately 1.07 g/ml (light), 1.20 g/ml (heavy) and 1.11 g/ml (normal HDL). The optical extinction coefficient is apparently the same for the proteins of normal--and modified HDL. 6. Even high CRM concentrations (less than or equal to 116 mg/ml) have no perceptible effect on the gradient positions and profile of human serum albumin (HSA) and/or other heavy proteins. 7. The possible biological significance of these findings is briefly touched upon.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015955     DOI: 10.1016/0020-711x(91)90176-n

Source DB:  PubMed          Journal:  Int J Biochem        ISSN: 0020-711X


  8 in total

Review 1.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice.

Authors:  José Hureaux; Frédéric Lagarce; Frédéric Gagnadoux; Marie-Christine Rousselet; Valérie Moal; Thierry Urban; Jean-Pierre Benoit
Journal:  Pharm Res       Date:  2010-03       Impact factor: 4.200

3.  In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy.

Authors:  Zhiping Zhang; Sie Huey Lee; Chee Wee Gan; Si-Shen Feng
Journal:  Pharm Res       Date:  2008-05-29       Impact factor: 4.200

4.  Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.

Authors:  L K Webster; E J Cosson; K H Stokes; M J Millward
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

5.  Tumour-localising and -photosensitising properties of a novel zinc(II) octadecylphthalocyanine.

Authors:  C Ometto; C Fabris; C Milanesi; G Jori; M J Cook; D A Russell
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

6.  Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.

Authors:  Lulu Cai; Xianhuo Wang; Wenwen Wang; Neng Qiu; Jiaolin Wen; Xingmei Duan; Xia Li; Xiang Chen; Li Yang; Zhiyong Qian; Yuquan Wei; Lijuan Chen
Journal:  Int J Nanomedicine       Date:  2012-08-14

7.  Effects of Cremophor EL on distribution of Taxol to serum lipoproteins.

Authors:  E Sykes; K Woodburn; D Decker; D Kessel
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

8.  Effect of axial ligation and delivery system on the tumour-localising and -photosensitising properties of Ge(IV)-octabutoxy-phthalocyanines.

Authors:  M Soncin; L Polo; E Reddi; G Jori; M E Kenney; G Cheng; M A Rodgers
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.